Antibodies against vaccine-preventable infections after CAR-T cell therapy for B cell malignancies

BACKGROUND Little is known about pathogen-specific humoral immunity after chimeric antigen receptor–modified T (CAR-T) cell therapy for B cell malignancies.METHODS We conducted a prospective cross-sectional study of CD19-targeted or B cell maturation antigen–targeted (BCMA-targeted) CAR-T cell thera...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JCI Insight
Main Authors: Carla S. Walti, Elizabeth M. Krantz, Joyce Maalouf, Jim Boonyaratanakornkit, Jacob Keane-Candib, Laurel Joncas-Schronce, Terry Stevens-Ayers, Sayan Dasgupta, Justin J. Taylor, Alexandre V. Hirayama, Merav Bar, Rebecca A. Gardner, Andrew J. Cowan, Damian J. Green, Michael J. Boeckh, David G. Maloney, Cameron J. Turtle, Joshua A. Hill
Formato: Artigo
Publicado em: American Society for Clinical investigation 2021-06-01
Assuntos:
Infectious disease
Oncology
Acesso em linha:https://doi.org/10.1172/jci.insight.146743
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Internet

https://doi.org/10.1172/jci.insight.146743

Registos relacionados